eGenesis’ goal is to advance the field of transplantation and make available safe and reliable xeno organs, tissues, and cells to patients in need. eGenesis uses gene editing technology such as CRISPR to directly address the key virology and immunology hurdles that have impeded xenotransplantation to date. eGenesis is advancing an initial product toward the clinic for kidney transplant, with the longer-term potential of addressing a broader organ recipient population and expanding the applicability of xenotransplantation into other areas such as cell therapy.

Contact eGenesis
Visit Website